PT2332989E - Estruturas de imunoglobulina que demonstram estabilidade aumentada no ambiente intracelular e métodos de identificação das mesmas - Google Patents
Estruturas de imunoglobulina que demonstram estabilidade aumentada no ambiente intracelular e métodos de identificação das mesmas Download PDFInfo
- Publication number
- PT2332989E PT2332989E PT100098573T PT10009857T PT2332989E PT 2332989 E PT2332989 E PT 2332989E PT 100098573 T PT100098573 T PT 100098573T PT 10009857 T PT10009857 T PT 10009857T PT 2332989 E PT2332989 E PT 2332989E
- Authority
- PT
- Portugal
- Prior art keywords
- methods
- enhanced stability
- intracellular environment
- demonstrate enhanced
- immunoglobulin frameworks
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
- C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38264902P | 2002-05-22 | 2002-05-22 | |
| US43825603P | 2003-01-03 | 2003-01-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2332989E true PT2332989E (pt) | 2015-08-05 |
Family
ID=29553590
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT100098573T PT2332989E (pt) | 2002-05-22 | 2003-05-21 | Estruturas de imunoglobulina que demonstram estabilidade aumentada no ambiente intracelular e métodos de identificação das mesmas |
| PT37324340T PT1506236E (pt) | 2002-05-22 | 2003-05-21 | Estruturas de imunoglobulina que demonstram estabilidade aumentada no ambiente intracelular e métodos de identificação das mesmas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT37324340T PT1506236E (pt) | 2002-05-22 | 2003-05-21 | Estruturas de imunoglobulina que demonstram estabilidade aumentada no ambiente intracelular e métodos de identificação das mesmas |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US8853362B2 (enExample) |
| EP (5) | EP2314622B1 (enExample) |
| JP (10) | JP2006508638A (enExample) |
| CN (4) | CN1662556B (enExample) |
| AU (2) | AU2003238370B2 (enExample) |
| CA (2) | CA2483285C (enExample) |
| CY (1) | CY1114225T1 (enExample) |
| DK (2) | DK1506236T3 (enExample) |
| ES (3) | ES2399617T3 (enExample) |
| HU (1) | HUE048922T2 (enExample) |
| NZ (1) | NZ536412A (enExample) |
| PT (2) | PT2332989E (enExample) |
| SI (2) | SI2332989T1 (enExample) |
| WO (1) | WO2003097697A2 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0226727D0 (en) * | 2002-11-15 | 2002-12-24 | Medical Res Council | Intrabodies |
| JP5171611B2 (ja) | 2005-03-25 | 2013-03-27 | ナショナル リサーチ カウンシル オブ カナダ | 可溶性ポリペプチドの単離方法 |
| AU2011265593B2 (en) * | 2005-06-07 | 2013-08-15 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies inhibiting TNFalpha |
| AU2016204739C1 (en) * | 2005-06-07 | 2017-10-19 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies inhibiting TNFalpha |
| KR101457223B1 (ko) | 2005-06-07 | 2014-11-04 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | ＴＮＦα를 억제하는 안정적이고 가용성인 항체 |
| AU2013207650B2 (en) * | 2005-06-07 | 2016-04-21 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies inhibiting TNFalpha |
| BRPI0710971A2 (pt) * | 2006-04-28 | 2011-05-31 | Esbatech Ag | anticorpos que se ligam ao domìnio extracelular do receptor tirosina cinase alk,seu uso, vetor de expressão,método para produção de um antcorpo, vacina e epìtodo de alk |
| ES2820837T3 (es) * | 2006-07-10 | 2021-04-22 | Esbatech Alcon Biomed Res Unit | Anticuerpos scFv que pasan las capas epitelial y/o endotelial |
| RU2009137582A (ru) * | 2007-03-12 | 2011-04-20 | Эсбатек Аг (Ch) | Инженерия и оптимизация одноцепочечных антител на основе последовательности |
| WO2008131575A2 (en) * | 2007-04-27 | 2008-11-06 | Esbatech Ag | Anti-alk antibodies suitable for treating metastatic cancers or tumors |
| BRPI0813645A2 (pt) * | 2007-06-25 | 2014-12-30 | Esbatech Alcon Biomed Res Unit | Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas |
| EP2164961B1 (en) * | 2007-06-25 | 2015-01-07 | ESBATech, an Alcon Biomedical Research Unit LLC | Sequence based engineering and optimization of single chain antibodies |
| US8323647B2 (en) | 2007-09-13 | 2012-12-04 | Delenex Therapeutics Ag | Humanized antibodies against the β-amyloid peptide |
| AU2015201794B2 (en) * | 2008-06-25 | 2017-01-19 | Novartis Ag | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa |
| BRPI0914251B1 (pt) | 2008-06-25 | 2022-07-19 | Novartis Ag | Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição |
| CA2728829C (en) | 2008-06-25 | 2018-01-02 | Esbatech, An Alcon Biomedical Research Unit Llc | Solubility optimization of immunobinders |
| PL2307458T3 (pl) * | 2008-06-25 | 2018-08-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała |
| AU2013202997B2 (en) * | 2008-06-25 | 2015-01-22 | Novartis Ag | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFalpha |
| AU2016273957C1 (en) * | 2008-06-25 | 2019-04-18 | Novartis Ag | STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa |
| KR102050040B1 (ko) * | 2008-06-25 | 2019-11-28 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | ＴＮＦα를 저해하는 안정한 가용성 항체 |
| KR20210097819A (ko) * | 2008-06-25 | 2021-08-09 | 노바르티스 아게 | 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화 |
| PL3628686T3 (pl) | 2008-06-25 | 2022-02-28 | Novartis Ag | Humanizowanie przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała |
| AU2009270405B2 (en) | 2008-06-30 | 2014-06-05 | Esbatech, An Alcon Biomedical Research Unit Llc | Functionalized polypeptides |
| EP2769711A1 (en) | 2008-07-10 | 2014-08-27 | ESBATech, an Alcon Biomedical Research Unit LLC | Methods and Compositions for Enhanced Delivery of Macromolecules |
| MX352922B (es) * | 2009-02-24 | 2017-12-14 | Esbatech Alcon Biomed Res Unit | Métodos para identificar inmunoligadores de los antígenos de la superficie celular. |
| AU2010217120B2 (en) | 2009-02-24 | 2014-11-20 | Novartis Ag | Methods for identifying immunobinders of cell-surface antigens |
| US8399625B1 (en) | 2009-06-25 | 2013-03-19 | ESBATech, an Alcon Biomedical Research Unit, LLC | Acceptor framework for CDR grafting |
| US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
| US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
| US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
| UY33679A (es) | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
| EP2476754A1 (en) * | 2011-01-14 | 2012-07-18 | Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts | Methods for the identification and repair of amino acid residues destabilizing single-chain variable fragments (scFv) |
| CA2845391C (en) | 2011-08-18 | 2021-01-19 | Affinity Biosciences Pty Ltd | Soluble polypeptides |
| CA2850572A1 (en) | 2011-10-20 | 2013-04-25 | Esbatech, A Novartis Company Llc | Stable multiple antigen-binding antibody |
| WO2014030780A1 (en) * | 2012-08-22 | 2014-02-27 | Mogam Biotechnology Research Institute | Screening and engineering method of super-stable immunoglobulin variable domains and their uses |
| BR112015009892B1 (pt) | 2012-11-05 | 2022-12-27 | Delenex Therapeutics Ag | Anticorpo contra il-1 beta, seu método de produção e seu uso, sequência isolada de ácido nucleico, vetor, composição cosmética, de diagnóstico ou farmacêutica, e kit |
| EP2931750B8 (en) | 2012-12-17 | 2021-11-03 | Cell Medica Inc. | Antibodies against il-1 beta |
| JP2016506974A (ja) * | 2013-02-15 | 2016-03-07 | エスバテック − ア ノバルティスカンパニー エルエルシー | Ｃｄｒグラフトのためのアクセプターフレームワーク |
| CA2896174A1 (en) * | 2013-02-20 | 2014-08-28 | Esbatech - A Novartis Company Llc | Acceptor framework for cdr grafting |
| RS61778B1 (sr) | 2013-05-06 | 2021-06-30 | Scholar Rock Inc | Kompozicije i postupci za modulaciju faktora rasta |
| US9737592B1 (en) | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
| US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| FI3218005T3 (fi) | 2014-11-12 | 2023-03-31 | Seagen Inc | Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| MY196631A (en) | 2015-10-13 | 2023-04-24 | Eureka Therapeutics Inc | Antibody Agents Specific for Human Cd19 and uses Thereof |
| MX2018004721A (es) | 2015-10-23 | 2018-07-06 | Eureka Therapeutics Inc | Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas. |
| CA3002097A1 (en) | 2015-11-12 | 2017-05-18 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| US20190048085A1 (en) | 2016-02-25 | 2019-02-14 | Cell Medica Switzerland Ag | Modified cells for immunotherapy |
| CN109952112B (zh) | 2016-09-21 | 2024-09-06 | 阿帕特夫研究和发展有限公司 | Cd123结合蛋白和相关的组合物和方法 |
| WO2018094143A1 (en) | 2016-11-17 | 2018-05-24 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| WO2018160909A1 (en) | 2017-03-03 | 2018-09-07 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| WO2019199941A1 (en) * | 2018-04-10 | 2019-10-17 | Northwestern University | Extracellular vesicles comprising targeting affinity domain-based membrane proteins |
| WO2020069349A1 (en) * | 2018-09-27 | 2020-04-02 | Colorado State University Research Foundation | Scfv's for live cell imaging and other uses |
| US12285437B2 (en) | 2019-10-30 | 2025-04-29 | The Research Foundation For The State University Of New York | Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity |
| TW202216761A (zh) | 2020-07-16 | 2022-05-01 | 瑞士商諾華公司 | 抗β細胞素抗體、其片段及多特異性結合分子 |
| JP2024509973A (ja) | 2021-03-10 | 2024-03-05 | マビュロン アーゲー | Ｔｄｐ－４３に対する抗体およびその使用方法 |
| US20250101089A1 (en) | 2022-01-24 | 2025-03-27 | Cambridge Enterprise Limited | Tau therapy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5817311A (en) * | 1993-03-05 | 1998-10-06 | Universite Catholique De Louvain | Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies |
| DE4425115A1 (de) | 1994-07-15 | 1996-01-18 | Boehringer Mannheim Gmbh | Verfahren zur Modifizierung der Stabilität von Antikörpern |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| US7264963B1 (en) * | 1995-08-18 | 2007-09-04 | Morphosys Ag | Protein(poly)peptide libraries |
| US6262238B1 (en) | 1997-01-14 | 2001-07-17 | Roche Diagnostic, Gmbh | Process for modifying the stability of antibodies |
| WO1999028502A1 (en) | 1997-11-28 | 1999-06-10 | Invitrogen Corporation | Single chain monoclonal antibody fusion reagents that regulate transcription in vivo |
| GB2344886B (en) | 1999-03-10 | 2000-11-01 | Medical Res Council | Selection of intracellular immunoglobulins |
| ATE273323T1 (de) * | 1999-12-28 | 2004-08-15 | Esbatech Ag | INTRAKÖRPER MIT DEFINIERTER STRUKTUR (ßFRAMEWORKß), DIE IN EINER REDUZIERENDEN UMGEBUNG STABIL IST, UND IHRE VERWENDUNGEN |
| GB0008419D0 (en) | 2000-04-05 | 2000-05-24 | Bioinvent Int Ab | A method for invitro molecular evolution of antibody function |
| EP1156062A1 (en) | 2000-05-12 | 2001-11-21 | GPC Biotech AG | Immunomodulatory human MHC class II antigen-binding peptides/proteins |
| US6410271B1 (en) | 2000-06-23 | 2002-06-25 | Genetastix Corporation | Generation of highly diverse library of expression vectors via homologous recombination in yeast |
| DE10039191C1 (de) | 2000-08-10 | 2002-01-17 | Infineon Technologies Ag | Hochfrequenz-Eingangsstufe |
-
2003
- 2003-05-21 JP JP2004506369A patent/JP2006508638A/ja not_active Withdrawn
- 2003-05-21 DK DK03732434.0T patent/DK1506236T3/da active
- 2003-05-21 CN CN038146266A patent/CN1662556B/zh not_active Expired - Lifetime
- 2003-05-21 EP EP10010455.3A patent/EP2314622B1/en not_active Expired - Lifetime
- 2003-05-21 EP EP15160739.7A patent/EP2947095B1/en not_active Expired - Lifetime
- 2003-05-21 ES ES03732434T patent/ES2399617T3/es not_active Expired - Lifetime
- 2003-05-21 US US10/515,241 patent/US8853362B2/en not_active Expired - Lifetime
- 2003-05-21 EP EP10009857.3A patent/EP2332989B1/en not_active Expired - Lifetime
- 2003-05-21 NZ NZ536412A patent/NZ536412A/en not_active IP Right Cessation
- 2003-05-21 ES ES10010455.3T patent/ES2656427T3/es not_active Expired - Lifetime
- 2003-05-21 DK DK10009857.3T patent/DK2332989T3/en active
- 2003-05-21 SI SI200332427T patent/SI2332989T1/sl unknown
- 2003-05-21 CN CN201510685456.0A patent/CN105175535A/zh active Pending
- 2003-05-21 CA CA2483285A patent/CA2483285C/en not_active Expired - Lifetime
- 2003-05-21 EP EP03732434A patent/EP1506236B1/en not_active Expired - Lifetime
- 2003-05-21 WO PCT/EP2003/005324 patent/WO2003097697A2/en not_active Ceased
- 2003-05-21 HU HUE15160739A patent/HUE048922T2/hu unknown
- 2003-05-21 CN CN201410031953.4A patent/CN103739706B/zh not_active Expired - Lifetime
- 2003-05-21 EP EP19200477.8A patent/EP3656787A1/en not_active Withdrawn
- 2003-05-21 AU AU2003238370A patent/AU2003238370B2/en not_active Expired
- 2003-05-21 PT PT100098573T patent/PT2332989E/pt unknown
- 2003-05-21 ES ES10009857.3T patent/ES2537104T3/es not_active Expired - Lifetime
- 2003-05-21 SI SI200332610T patent/SI2947095T1/sl unknown
- 2003-05-21 CN CN201010575786.1A patent/CN102093477B/zh not_active Expired - Lifetime
- 2003-05-21 PT PT37324340T patent/PT1506236E/pt unknown
- 2003-05-21 CA CA2867542A patent/CA2867542C/en not_active Expired - Lifetime
-
2010
- 2010-03-17 JP JP2010060713A patent/JP2010187678A/ja not_active Withdrawn
- 2010-06-24 AU AU2010202634A patent/AU2010202634B2/en not_active Expired
-
2012
- 2012-08-28 JP JP2012187518A patent/JP6075836B2/ja not_active Expired - Lifetime
-
2013
- 2013-02-04 JP JP2013019425A patent/JP6100544B2/ja not_active Expired - Lifetime
- 2013-04-08 CY CY20131100292T patent/CY1114225T1/el unknown
- 2013-09-19 JP JP2013193935A patent/JP2013256533A/ja active Pending
-
2014
- 2014-08-26 US US14/469,276 patent/US9518108B2/en not_active Expired - Fee Related
-
2015
- 2015-08-19 JP JP2015161600A patent/JP6261136B2/ja not_active Expired - Lifetime
- 2015-08-19 JP JP2015161601A patent/JP2015214583A/ja active Pending
-
2016
- 2016-11-01 US US15/340,195 patent/US10125186B2/en not_active Expired - Lifetime
-
2017
- 2017-08-24 JP JP2017161036A patent/JP2017201990A/ja active Pending
-
2018
- 2018-10-30 US US16/175,002 patent/US10570190B2/en not_active Expired - Fee Related
-
2019
- 2019-01-23 JP JP2019009288A patent/JP6918033B2/ja not_active Expired - Lifetime
- 2019-12-16 US US16/716,137 patent/US20200165322A1/en not_active Abandoned
-
2020
- 2020-05-14 JP JP2020085288A patent/JP2020171286A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2947095T1 (sl) | Imunoglobulinski bralni okvirji, ki kažejo izboljšano stabilnost v znotrajceličnem okolju, in postopki za njihovo identifikacijo | |
| TWI370816B (en) | 6-alkyl or alkenyl-4-aminopicolinates and their use as herbicides | |
| EP1546112A4 (en) | IMIDAZOLOPYRIDINE AND METHOD FOR THE PRODUCTION AND USE THEREOF | |
| AU2003282478A8 (en) | Discount-instrument methods and systems | |
| AU2003267279A8 (en) | Systems and methods for transformable suits | |
| PL381765A1 (pl) | Konstrukty wiążące i sposoby ich zastosowania | |
| GB0619264D0 (en) | Methods and lens | |
| EP1539941A4 (en) | ADZYMES AND THEIR USES | |
| ZA200603882B (en) | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides | |
| IL175491A0 (en) | Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides | |
| EP1550923A4 (en) | THREE-DIMENSIONAL DISPLAY AND METHOD FOR THREE-DIMENSIONAL DISPLAY | |
| EG24579A (en) | Herbicide composition and weed-controlling method using the same | |
| AU2003265562A8 (en) | Computer-aided education systems and methods | |
| GB0202059D0 (en) | Chemical compositions and methods | |
| AU2003296369A8 (en) | Imminoamines and preparation thereof | |
| SI1551805T1 (sl) | Substituirani gama-fenil-delta-laktami in njihova uporaba | |
| GB2408530B (en) | Well completion systems and methods | |
| IL172510A0 (en) | Antibodies and uses thereof | |
| AU2002346446A1 (en) | Methods and compositions in checkpoint signaling | |
| AU2003297612A8 (en) | 2-substituted-3-propenamide derivatives and methods of using the same | |
| IL166063A0 (en) | Antibodies and uses thereof | |
| SG112011A1 (en) | Laser micromachining and methods of same | |
| AU2003231827A8 (en) | Pseudo-tissues and uses thereof | |
| GB0318546D0 (en) | Quinoxalinones and their use | |
| SI1506236T1 (sl) | Imunoglobulinski bralni okvirji, ki kažejo izboljšano stabilnost v intraceličnem okolju in postopki za njihovo identifikacijo |